A
Acacia Pharma
Hospital pharmaceuticals for surgery-related side effects
About Acacia Pharma
Acacia Pharma is a biopharmaceutical company focused on developing and commercializing products for patients undergoing surgery, invasive procedures, or chemotherapy. Founded in 2007 by individuals including Julian Clive Gilbert and Gabriel Max Fox, the company aimed to address unmet needs in supportive care. Their expertise in clinical and pharmaceutical development guided the company through significant milestones, including an IPO on the Euronext Brussels exchange in 2018.
The company's business model centers on identifying, developing, and commercializing specialized hospital products in the US. Its main products are BARHEMSYS® and BYFAVO®. BARHEMSYS® (amisulpride injection) is an antiemetic used for the treatment and prevention of postoperative nausea and vomiting (PONV). It is the first and only product approved for rescue treatment of PONV in patients who have not responded to initial prophylaxis. BYFAVO® (remimazolam for injection) is an intravenous benzodiazepine sedative used for sedation during short medical procedures, such as colonoscopies, lasting 30 minutes or less. This product was in-licensed for the US market. The company also has a late-stage candidate, APD403, for chemotherapy-induced nausea and vomiting (CINV).
In June 2022, Acacia Pharma was acquired by Eagle Pharmaceuticals, Inc., in a deal valued at approximately $104 million. The acquisition was a strategic move for Eagle to expand its acute care and hospital product portfolio, integrating Acacia's commercialized assets into its existing sales infrastructure. Following the acquisition, Acacia Pharma operates as a subsidiary of Eagle Pharmaceuticals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
News
Open roles
Acacia Pharma in the Cambridge ecosystem
The Acacia Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Lundbeckfonden
Lundbeckfonden Ventures
Gilde Healthcare
F-Prime
Novo Seeds
Novo Holdings
Series B and later1 investor entered at this stage
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
See Acacia Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

